Welcome to our dedicated page for Inmune Bio SEC filings (Ticker: INMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
INmune Bio Inc.'s SEC filings document the disclosure record of a Nasdaq-listed Nevada biotechnology company developing innate-immune therapies. Its filings identify common stock traded under INMB and cover material-event reports, Regulation FD presentations, shareholder letters, clinical and regulatory updates, operating and financial results, and capital-structure disclosures.
Recent 8-K filings include disclosures tied to product-platform communications and a material definitive agreement involving INmune Bio International and Anthony Nolan for the CORDStrom platform. Proxy materials cover shareholder voting and governance matters, while the company’s formal disclosures frame recurring risks and development-stage issues associated with biotechnology research, regulatory pathways, collaborations and financing.
INmune Bio Inc. filed a current report to note that it issued a press release on January 27, 2026 announcing a shareholder letter. The letter is intended to provide shareholders with updates on the company’s prior and future operations.
The press release is included as Exhibit 99.1 and, along with the related disclosure, is being furnished under Regulation FD rather than filed. As a result, this information is not subject to certain liability provisions of the federal securities laws and will not be incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
Inmune Bio, Inc. (INMB) reported a stock option repricing for a director effective as of November 18, 2025. Stockholders approved a one-time adjustment that reduced the exercise price of certain outstanding stock options granted under the company’s 2017, 2019 and 2021 stock incentive plans to $1.50 per share, matching the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on that date. The filing shows multiple stock option awards where higher exercise prices were replaced by new options at $1.50, while all other terms, including vesting schedules and expiration dates, remain unchanged and continue to depend on the director’s ongoing service.
Inmune Bio, Inc. (INMB) reported that its Chief Executive Officer and director had multiple outstanding stock option awards repriced on November 18, 2025. Stockholders approved a one-time repricing of certain options granted under the company’s 2017, 2019, and Second Amended and Restated 2021 Stock Incentive Plans, reducing the exercise price of each affected option to $1.50, which was the company’s Nasdaq closing share price on the repricing date. For example, one stock option covering 400,000 shares originally exercisable at $7.80 was adjusted to a $1.50 exercise price. The filing states that all other terms of these repriced options, including vesting schedules and terms, remain unchanged, and exercisability continues to depend on the CEO’s ongoing service.
Inmune Bio (INMB) reported a Form 4 filing for its Chief Scientific Officer, Mark William Lowdell, reflecting a one-time repricing of certain outstanding stock options. Effective as of November 18, 2025, stockholders approved reducing the exercise price of these options granted under the 2017, 2019 and Second Amended and Restated 2021 Stock Incentive Plans to $1.50, equal to the Nasdaq Capital Market closing price of the company’s common stock on that date. The table shows multiple existing stock option grants being adjusted from higher exercise prices to $1.50 while keeping the same share amounts and expiration dates. All other terms, including vesting and option terms, remain in full force and effect, so the change mainly affects the price at which these options can be exercised.
Inmune Bio, Inc. (INMB) reported a one-time repricing of certain outstanding stock options for a company director effective November 18, 2025. The stockholders approved reducing the exercise price of these existing options to $1.50 per share, which matches the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on that date. Multiple previously granted stock options with higher exercise prices, covering blocks such as 108,000, 35,000, 32,500 and other share amounts, were cancelled and replaced with new options for the same number of underlying common shares at the new $1.50 exercise price. All other terms of the repriced options, including vesting schedules and expiration dates under the company’s 2017, 2019 and 2021 stock incentive plans, remain unchanged.
Inmune Bio, Inc. (INMB) director reprices stock options following shareholder approval. On November 18, 2025, the company’s stockholders approved a one-time repricing of certain outstanding stock options granted under Inmune Bio’s 2017, 2019 and 2021 stock incentive plans. The repricing reduced the per-share exercise price of each affected option to $1.50, which was the closing price of Inmune Bio common stock on The Nasdaq Capital Market on the repricing date. The table shows prior options with exercise prices such as $7.80, $3.91, $24.82, $17.49, and others being replaced with new options at $1.50 for the same share amounts, including grants of 108,000 and 35,000 shares. All other terms of these options, including vesting schedules and expiration dates, remain unchanged and continue to depend on the director’s ongoing service.
Inmune Bio, Inc. (INMB) reported a change in the stock options held by its interim CFO, Cory Randall Ellspermann. On November 18, 2025, shareholders approved a one-time repricing of certain outstanding options granted under the company’s 2017, 2019 and 2021 stock incentive plans. The repricing reduced the exercise price of each affected option to $1.50 per share, which was the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on that date.
The Form 4 shows cancellations of existing stock options with higher exercise prices and the grant of replacement options at the new $1.50 exercise price for the same numbers of underlying shares and original expiration dates. All other terms of these options, including vesting schedules and overall terms, remain unchanged and continue to depend on the executive’s ongoing service with the company.
Inmune Bio, Inc. (INMB) director Marcia Allen reported a repricing of her stock options, following stockholder approval effective November 18, 2025. Certain existing options granted under the company’s 2017, 2019 and 2021 stock incentive plans had their exercise price reduced to $1.50 per share, matching the Nasdaq closing price of Inmune Bio’s common stock on the repricing date. The filing shows prior options with higher exercise prices, including awards at $3.91, $7.92, $9.74, $17.49, $24.82 and $5.05, being adjusted so that the same numbers of underlying shares remain, but at the new exercise price. All other terms of these options, such as vesting schedules and expiration dates, remain unchanged, and the awards continue to be tied to Allen’s ongoing service with the company.
INmune Bio Inc. reported that stockholders approved a one-time repricing of certain outstanding stock options covering up to 5,511,000 shares under its equity incentive plans. Effective November 18, 2025, the exercise price of these options for eligible employees and directors was reduced to $1.50 per share, matching the Nasdaq closing price that day, while all other option terms remain unchanged.
At the special meeting, 26,585,258 shares were entitled to vote, with 10,193,242 shares represented, establishing a quorum. The option repricing proposal passed with 7,144,433 votes for, 2,926,973 against, and 121,836 abstentions. INmune Bio also announced in a press release that it will deliver two presentations at the 18th Clinical Trials on Alzheimer’s Disease conference in San Diego from December 1–4, 2025.
INmune Bio (INMB) furnished an Investor Presentation under Regulation FD. The company reported via an 8-K that a slide deck intended for periodic presentations was made available as Exhibit 99.1. The disclosure is provided under Item 7.01, which is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference.
The filing also lists Exhibit 104 for the cover page interactive data file embedded within the Inline XBRL document.